Current Issues in the Diagnosis and Treatment of Endometrial Carcinoma

Stubert, Johannes; Gerber, Bernd

doi:10.1055/s-0035-1558230

Cited by 18 publications

(12 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No adverse reactions of Grade 3 or above were found in the follow-up period after treatment. Currently, many studies are combining molecular targeted therapy with clinicopathological risk factors, which can distinguish patients who require less or more intensified adjuvant treatment [ 24 , 25 ]. However, more evidence is needed, and randomized trials are necessary.…”

Section: Discussionmentioning

confidence: 99%

Treatment optimization of pelvic external beam radiation and/or vaginal brachytherapy for patients with stage I to II high-risk Endometrioid adenocarcinoma: a retrospective multi-institutional analysis

et al. 2021

View full text Add to dashboard Cite

Background For stage I to II high-risk endometrioid adenocarcinoma patients, the optimal adjuvant radiotherapy modality remains controversial. The present study sought to optimize the treatment of pelvic external beam radiation (EBRT) with/or vaginal brachytherapy (VBT) for high-risk endometrioid adenocarcinoma patients in multiple radiation oncology centers across China. Methods This article retrospectively reviewed stage I to II patients with resected endometrioid adenocarcinoma treated at 13 radiation centers from 1999 to 2015. Patients were eligible if they had high-risk features (stage IB Grade 3 disease or stage II Grade 1–3 disease) on the basis of ESMO-ESGO-ESTRO risk group consensus. Results A total of 218 patients were included. Fifty-one patients received EBRT, 25 patients received VBT, and 142 patients were administered EBRT combined with VBT. The three groups were comparable in baseline characteristics, except the proportion of stage IB and Grade 3 disease in the VBT group was significantly higher and their age was older. Survival analysis showed that OS, DFS, LRFS and DMFS were significantly different among the three groups. Two out of three groups were compared with each other, and results demonstrated that DFS, LRFS and DMFS were worse in the VBT group than in the EBRT or EBRT + VBT group. The 3-year OS rates were 95.2, 85.2 and 95.1% in the EBRT, VBT and EBRT + VBT groups, respectively (p = 0.043). There was no significant difference in survival outcomes between EBRT group and EBRT + VBT group. A propensity matching analysis was performed to eliminate group differences. The results demonstrated that DFS and LRFS were significantly improved in the pelvic radiation group compared to the VBT group. Distant failure accounted for most of the failure patterns. Patients in the VBT group had significantly increased local and regional recurrence rates than patients in the EBRT or EBRT + VBT group. Acute and chronic radiation-induced toxicities were well tolerated for all patients. Conclusion For patients with postoperative stage I to II high-risk endometrioid adenocarcinoma, compared with VBT alone, radiotherapy modalities including EBRT significantly improved DFS, LRFS and DMFS with tolerable adverse effects. Overall survival was not significantly different between EBRT and EBRT + VBT modalities.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment optimization of pelvic external beam radiation and/or vaginal brachytherapy for patients with stage I to II high-risk Endometrioid adenocarcinoma: a retrospective multi-institutional analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…According to the literature, abnormal postmenopausal bleeding is the first symptom of endometrial cancer and the most common clinical diagnosis with which patients are referred to a physician for examination and referred for fractional curettage. As much as 66 % of endometrial cancers are detected due to this symptom 34,35 . It should be emphasized that, although the most common first symptom of endometrial cancer is bleeding, the very occurrence of irregular bleeding may not necessarily indicate the existence of endometrial cancer, since endometrial hyperplasia and atrophy are more common causes of irregular bleeding 36 .…”

Section: Discussionmentioning

confidence: 99%

The difference in histological grades of endometrial carcinoma in curettage and hysterectomy – cross-sectional study

Franjić

Vranješ

Milić

et al. 2020

Med. Flum. (Online)

View full text Add to dashboard Cite

Objectives: To determine the compatibility rate between histological grades of endometrial carcinoma in curettage and hysterectomy and to determine how quantity of material, given by the method of fractional hysterectomy, affects the compatibility between histological grades in the two methods. Material and methods: The study included 102 patients with endometrioid endometrial cancer who underwent methods of fractional curettage and hysterectomy. Data regardingthepathohistological status of uterine tissue was obtained from the available medical records. Information on age andclinical diagnoses were obtained from referrals for pathohistologicaltissue examination. The age of the subjects was determined at the time when the tissue samples were taken for analysis. Data on the amount of material was obtained from the description of macroscopic evaluation of the given material. Results: Most subjects had grade II endometrioid endometrial cancer (47.1 % and 50 %). Most of the respondents had a medium deficient material obtained by fractional curettage (40.2 %). There was no statistically significant difference between the histological grade determined after the fractional curettage and hysterectomy. There were no statistically significant differences in histological grade in the sample obtained by fractional curettage and hysterectomy depending on the amount of material in fractional curettage. Conclusions: There was no statistically significant differences in the grade of endometrial cancer in samples obtained by the fractional curettage and hysterectomy. The correspondence is higher in higher tumor grade (III), and lower in lower tumor grades (I, II). The amount of material did not affect the grade deviation in the sample obtained by fractional curettage and hysterectomy.

show abstract

“…Recently, the incidence of EC has been rising annually and the disease onset has gradually become younger [5]. Despite most EC patients can be diagnosed and treated in the early stage of EC, approximately 15% of EC patients are diagnosed with advanced or occult metastases, resulting in poor outcome and even high mortality [6][7][8]. Generally speaking, accumulation of multiple genetic abnormalities (which is likely to inactivate tumor-suppressor genes and activate oncogenes) lead to the arise of EC [9].…”

Section: Introductionmentioning

confidence: 99%

STYX/FBXW7 axis participates in the development of endometrial cancer cell via Notch–mTOR signaling pathway

et al. 2020

View full text Add to dashboard Cite

Endometrial cancer (EC) is the most common gynecologic malignancy in world. It has been reported that the mutation rate of FBXW7 is frequent in EC, but the specific functions of FBXW7 remain unknown in EC. In the present study, we revealed the role and mechanism of FBXW7 in EC cells. Compared with adjacent nontumor tissues, the FBXW7 expression level was lower in EC tissues. However, the level of STYX was in contrast with the expression of FBXW7 in EC tissues. And STYX interacted with FBXW7 and then down-regulated its expression level in EC. Over-expression of FBXW7 inhibited cell proliferation and facilitated apoptosis in EC cells, whereas silencing FBXW7 acted an opposite effect on EC cells. And the process of FBXW7 participated the proliferation and apoptosis in EC was regulated by STYX. FBXW7 suppressed the expression of Notch pathway related protein, and further inhibited the phosphorylation of mTOR. In addition, we also found that mTOR activitor (MHY1485) and Notch activator (Jagged-1) reversed the effect of over-expressing FBXW7 on cell proliferation and cell apoptosis. And Notch inhibitor (DAPT) counteracted the impact of over-expressing STYX on cell proliferation and cell apoptosis. Collectively, the present study verified that STYX inhibited the expression level of FBXW7 in EC, and then promoted cell proliferation but suppressed apoptosis through Notch–mTOR signaling pathway, which promoted carcinogenesis and progression of EC.

show abstract

Current Issues in the Diagnosis and Treatment of Endometrial Carcinoma

Cited by 18 publications

References 45 publications

Treatment optimization of pelvic external beam radiation and/or vaginal brachytherapy for patients with stage I to II high-risk Endometrioid adenocarcinoma: a retrospective multi-institutional analysis

Treatment optimization of pelvic external beam radiation and/or vaginal brachytherapy for patients with stage I to II high-risk Endometrioid adenocarcinoma: a retrospective multi-institutional analysis

The difference in histological grades of endometrial carcinoma in curettage and hysterectomy – cross-sectional study

STYX/FBXW7 axis participates in the development of endometrial cancer cell via Notch–mTOR signaling pathway

Contact Info

Product

Resources

About